{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "I",
          "alt": "T",
          "position": 2020
        },
        "variant_string_id": "LRRK2 I2020T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in leucine-rich repeat kinase 2 (LRRK2) are a frequent cause of late-onset autosomal dominant Parkinson’s disease (PD).",
          "judgment": "Yes",
          "reasoning": "论文明确指出LRRK2基因突变是迟发性常染色体显性帕金森病的常见原因。"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "We demonstrate by both binding and enzymatic assays that alterations in the kinase activity of the PD-associated mutants I2020T and G2019S are due in part to altered ATP affinity.",
          "judgment": "Yes",
          "reasoning": "论文使用了结合和酶活性测定来研究突变对激酶活性的影响，这些方法能够有效反映疾病机制。"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "Step 3a: Basic Controls and Replicates: Kinase reactions were performed in duplicate at room temperature... Kinase concentrations were 10 nM for wild-type and I2020T and 4.9 nM for G2019S.\n\nStep 3c: Variant Controls: G2019S has higher activity in kinase activity assays and was recently shown to have an altered ATP Km,app. I2020T has lower kinase activity in assays measuring substrate phosphorylation.",
          "judgment": "Yes",
          "reasoning": "Step 3a: Basic Controls and Replicates: 实验使用了野生型和突变型作为对照，并且所有实验均重复进行。\n\nStep 3c: Variant Controls: 实验中使用了已知的致病性突变（如G2019S）作为阳性对照。"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "Step 4b: No OddsPath Calculation: I2020T showed both lower Vmax and a much lower ATP Km,app than wild-type. The ATP Km for I2020T was found to be 7.5 ± 0.4 μM, which is 7-fold lower than that for wild-type LRRK2.",
          "judgment": "Yes",
          "reasoning": "Step 4b: No OddsPath Calculation: 虽然没有直接计算OddsPath，但提供了足够的统计数据来支持变异的功能影响。"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "LRRK2 I2020T变异导致ATP亲和力显著提高和Vmax降低，这表明该变异可能在细胞水平上对ATP竞争性抑制剂产生抗性，支持其致病性。"
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": 2019
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in leucine-rich repeat kinase 2 (LRRK2) are a frequent cause of late-onset autosomal dominant Parkinson’s disease (PD).",
          "judgment": "Yes",
          "reasoning": "论文明确指出LRRK2基因突变是迟发性常染色体显性帕金森病的常见原因。"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "We demonstrate by both binding and enzymatic assays that alterations in the kinase activity of the PD-associated mutants I2020T and G2019S are due in part to altered ATP affinity.",
          "judgment": "Yes",
          "reasoning": "论文使用了结合和酶活性测定来研究突变对激酶活性的影响，这些方法能够有效反映疾病机制。"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "Step 3a: Basic Controls and Replicates: Kinase reactions were performed in duplicate at room temperature... Kinase concentrations were 10 nM for wild-type and I2020T and 4.9 nM for G2019S.\n\nStep 3c: Variant Controls: G2019S has higher activity in kinase activity assays and was recently shown to have an altered ATP Km,app.",
          "judgment": "Yes",
          "reasoning": "Step 3a: Basic Controls and Replicates: 实验使用了野生型和突变型作为对照，并且所有实验均重复进行。\n\nStep 3c: Variant Controls: 实验中使用了已知的致病性突变（如G2019S）作为阳性对照。"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "Step 4b: No OddsPath Calculation: The ATP Km,app value for G2019S (169 μM) was approximately 3-fold higher than wild-type LRRK2 (51 μM), whereas the specific activity for G2019S was approximately 3-fold higher.",
          "judgment": "Yes",
          "reasoning": "Step 4b: No OddsPath Calculation: 虽然没有直接计算OddsPath，但提供了足够的统计数据来支持变异的功能影响。"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "LRRK2 G2019S变异导致ATP亲和力显著降低和激酶活性增加，这表明该变异可能在细胞水平上对ATP竞争性抑制剂更为敏感，支持其致病性。"
    }
  ]
}